eli lilly glp-1 winner US approves new oral weight-loss pill developed by | US news US approves new oral weight-loss
Description
Promising clinical trial data suggests big opportunity with Eli Lilly's retatrutide GLP-1 candidate.
A new era for weight loss
The development of dual GIPRGLP1R coagonists that bind to either one or the other receptor (sequence-mixed dual agonists) has emerged as an innovative therapeutic strategy for obesity and type 2 diabetes
Learn how to switch from tirzepatide to retatrutide safely
Learn why semaglutide weight loss plateaus happen and how to break them with better consistency, calorie tweaks, protein, and strength training.
